Both the companies anticipate that this timely re-commitment will reap mutual benefits, as the growing body of AC-11 scientific validation recently has opened several new doors for capitalizing on Optigenex’s patented technology, especially in the novel field of advanced, oral-based sun care products.
Jeff Wuagneux, president and CEO of RFI, said: “Over the past several years we have come to value the science behind AC-11, and Optigenex’s commitment to furthering the clinical validation of the technology. RFI is dedicated to promoting and marketing science based products, and we feel confident that AC-11 will have a great impact as a key strategic component in both the oral-based sun care market, as well as the DNA repair and antioxidant categories.”
Daniel Zwiren, president and CEO of Optigenex, said: “The signing of this expanded agreement was an easy decision for us, because RFI in an impressive fashion has grown its business vertically from wholesale ingredient supplier to a finished product, direct to consumer marketing company. We are confident that RFI is positioned to market AC-11 on a large scale to health conscious, educated consumers in North America.”